Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long term to prevent major cardiovascular, neurological, or bleeding events. Moreover, procedures not related to prosthesis implantation saw significant reduction.

Cierre de orejuela vs anticoagulantes directos a largo plazo

The PRAGUE-17 was a randomized non-inferiority study comparing left atrial appendage closure (Watchman or Amulet) with direct anticoagulants (95% received apixaban) in patients with non-valvular atrial fibrillation in addition to a history of cardio-embolism, clinically relevant bleeding or both (CHA2DS2-VASc ≥3). 

Primary end point was a combination of cardioembolic events (stroke, transient ischemic attack, or systemic thromboembolism), cardiovascular death, clinically relevant bleeding, or procedure related complications (only for atrial appendage closure).

It included 201 patients in each group (mean age 73.3 ± 7.0). After 3.5 year mean follow-up, atrial appendage closure resulted non inferior to direct anticoagulants for primary end point. 


Read also: PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents.


Primary end point resulted similar for both for treatment intention and protocol analysis. 

Conclusion

At long term followup, left atrial appendage closure resulted non inferior to direct anticoagulants in the prevention of cardiovascular, neurological, and bleeding events. After device implantation, bleeding saw significant reduction with these devices.

Original Title: 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation.

Reference: Pavel Osmancik et al. J Am Coll Cardiol. 2022 Jan 4;79(1):1-14. doi: 10.1016/j.jacc.2021.10.023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...